List of Elucirem drug patents
Elucirem is owned by Guerbet.
Elucirem contains Gadopiclenol.
Elucirem has a total of 2 drug patents out of which 0 drug patents have expired.
Elucirem was authorised for market use on 21 September, 2022.
Elucirem is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Elucirem from 2026-09-21.
The generics of Elucirem are possible to be released after 06 August, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8114863 | GUERBET | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging |
Sep, 2028
(5 years from now) | |
| US10973934 | GUERBET | Gadolinium bearing PCTA-based contrast agents |
Aug, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 2026-09-21
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
ELUCIREM family patents
9
European Union
8
United States
5
Japan
3
Korea, Republic of
3
Spain
3
Canada
3
China
2
Portugal
2
Poland
2
France
2
Denmark
2
Brazil
1
Australia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic